Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Table 2
Tumor characteristics of patients.
Variables
HCC on NAFLD (n = 56)
HCC on ALD (n = 173)
HCC on HBV (n = 393)
value
Modality of initial tumor detection
Surveillance, n (%)
43 (76.8%)
148 (85.5%)
352 (89.6%)
0.025
Incidental, n (%)
6 (10.7%)
7 (4.0%)
6 (1.5%)
0.001
Symptomatic, n (%)
7 (12.5%)
18 (10.4%)
35 (8.9%)
0.643
Size of largest tumor (cm), mean (SD)
6.2 (3.4)
3.7 (3.6)
4.5 (4.0)
0.001
Number of nodules, mean (SD)
2.1 (1.6)
2.2 (1.6)
2.1 (1.6)
0.944
Milan out, n (%)
35 (62.5%)
62 (35.8%)
184 (46.8%)
0.001
Barcelona clinic liver cancer
Stage 0, n (%)
3 (5.4%)
24 (13.9%)
70 (17.8%)
0.043
Stage A, n (%)
18 (32.1%)
76 (43.9%)
128 (32.6%)
0.029
Stage B, n (%)
12 (21.4%)
28 (16.2%)
68 (17.3%)
0.666
Stage C, n (%)
20 (35.7%)
22 (12.7%)
91 (23.2%)
<0.001
Stage D, n (%)
3 (5.4%)
23 (13.3%)
36 (9.2%)
0.154
Infiltrative, n (%)
15 (26.8%)
23 (13.3%)
59 (15.0%)
0.047
Extrahepatic metastasis, n (%)
17 (30.4%)
35 (20.2%)
108 (27.5%)
0.136
Lymphatic node metastasis, n (%)
6 (10.7%)
13 (7.5%)
44 (11.2%)
0.404
Macrovascular infiltration, n (%)
17 (30.4%)
33 (19.1%)
118 (30.0%)
0.022
α-FP (ng/dL), median (range)
182.0 (1–137648)
26.8 (0.2–150000)
70.5 (0–150000)
<0.001
PIVKAII (mAU/ml), median (range)
654.5 (5–199000)
94.5 (2–457000)
45.5 (6–230642)
0.003
HCC: hepatocellular carcinoma; NAFLD: nonalcoholic fatty liver disease; ALD: alcoholic liver disease; HBV: hepatitis B virus; SD: standard deviation; α-FP: alpha-fetoprotein; PIVKAII: protein induced by vitamin K absence or antagonist-II.
